Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme Therapeutics has reported the positive data from two phase 1 studies of PEGPH20 targeting hyaluronan in tumor stroma.
Subscribe to our email newsletter
Study 101 evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PEGPH20 as a single agent, while Study 102 assessed multiple-dosing of PEGPH20 in combination with dexamethasone.
The results demonstrated that PEGPH20 treatment rapidly restored tumor perfusion and decreased metabolic activity in tumors.
Moreover, Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) showed that the imaging agent was able to access a pancreatic tumor more easily post-administration of PEGPH20.